Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 6/20 | 0.68 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | COMT | P21964 | 4/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30740931 | 0.83 | FTO (0.53) | FTOEGFRCOMTTTRJUN | |
| SCHEMBL32669845 | 0.83 | FTO (0.72) | FTOCOMTTTRMAPTKDM4E | |
| SCHEMBL32669893 | 0.83 | FTO (0.53) | FTOEGFRCOMTTTRJUN | |
| SCHEMBL32669703 | 0.82 | FTO (0.58) | FTOEGFRCOMTTTRJUN | |
| SCHEMBL32669734 | 0.81 | FTO (0.52) | FTOEGFRCOMTTTRMAPT | |
| SCHEMBL31520158 | 0.80 | FTO (0.53) | FTOEGFRCOMTTTRMAPT | |
| SCHEMBL32669761 | 0.80 | FTO (0.77) | FTOEGFRCOMTTTRJUN | |
| SCHEMBL32670075 | 0.79 | FTO (0.54) | FTOEGFRCOMTTTRJUN | |
| SCHEMBL32670126 | 0.78 | FTO (0.56) | FTOEGFRCOMTTTRJUN | |
| SCHEMBL32670042 | 0.78 | FTO (0.56) | FTOEGFRCOMTTTRJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4561975-A1 | FTO INHIBITORS | RPXDS Co., Ltd (CN) | 2025-06-04 | — | — | EP | disclosed |
| CN-119546566-A | FTO inhibitors | 瑞璞鑫(苏州)生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024022491-A1 | FTO INHIBITORS | RPXDS CO., LTD (CN) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | FTO 1/4885EGFR 897/4885COMT 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.